• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 June 2013
 

European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 June 2013

on

  • 383 views

European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 June 2013, presented by Jan Geissler (@jangeissler), Director EUPATI (@EUPATIents) at the IMI's "Patient Focus" meeting, ...

European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 June 2013, presented by Jan Geissler (@jangeissler), Director EUPATI (@EUPATIents) at the IMI's "Patient Focus" meeting, convening patient leaders from across Europe

Statistics

Views

Total Views
383
Views on SlideShare
355
Embed Views
28

Actions

Likes
0
Downloads
0
Comments
0

1 Embed 28

https://twitter.com 28

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 June 2013 European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 June 2013 Presentation Transcript

    • Jan Geissler – EUPATI Directorhttp://www.patientsacademy.eu – jan@patientsacademy.euIMI Patient Focus Meeting, 12 June 2013European Patients’ Academyon Therapeutic InnovationThe project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composedof financial contribution from the European Unions Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.
    • Medical landscape is changingat a fast paceInnovation transforms the lives ofpatients with serious, lifelong conditions: Molecular targets/pathways Genome sequencing, Translational research Personalized medicine• Small trial populations• Biomarkers, companion diagnostics Need for post-marketing data Health Technology Assessment,QoL, endpoints, comparators BUT long term pressure on health budgets– here to stayWindow ofopportunity trial design relationshipbetweenresearchers,regulators,industry,patients2
    • PublicResearch EthicsCommitteesCompetentauthoritiesPolicy makersHTA agencies& committeesResearch subjectInfo providerAdvisorReviewerCo-researcherDriving forceClinicalResearchFor patient-centric medicines R&D,we need more trained patient advocatesTrial protocoldesign, informedconsent, ethicalreview, marketingauthorization, valueassessment, health policy
    • The Patients’ Academy: Paradigm shift inempowering patients on medicines R&D Launched Feb ’12, runs for 5 years,30 consortium members,Funded by IMI JU will develop and disseminateobjective, credible,correct and up-to-date publicknowledge about medicinesR&D will build competencies& expert capacity among patients & public will facilitate patient involvement in R&D to collaborate in academicresearch, industry research, authorities and ethics committees
    • Areas covered bythe European Patients’ AcademyExample: EUPATI Face2Face Training Courses1. Discovery of Medicines & Planning of Medicines Development2. Non-Clinical Testing and Pharmaceutical Development3. Exploratory and Confirmatory Clinical Development4. Clinical Trials5. Regulatory Affairs, Medicinal product Safety, Pharmacovigilanceand Pharmaco-epidemiology6. Health Technology Assessment and theeconomics…and NOT:develop indication-or therapy-specificinformation!
    • Reflecting European diversity:7 languages, 12 countries 7 most frequently spoken languages:English, French, German, Spanish, Polish,Italian, Russian Serving 12 European countriesATBECHDEESFRITIELUMTPLUK
    • EUPATI Internet LibraryEUPATI Educational ToolboxEUPATI Training ProgrammeTo bring this to life, EUPATI developseducation targeted at different levels100“expert”patientadvocates12.000patientadvocates100.000individuals
    • Project led by 4 key pan-Europeanpatient associations◦ EUPATI Project Coordination◦ >50 umbrella patient organisations.◦ Linking national and regional patientalliances◦ >550 rare disease organisations in>45 countries◦ >100 members in over 30 countriesAdditionalpartners in otherpatientorganisationsand "membersof members"via"EUPATINetwork"
    •  Led by pan-EU patient umbrellagroups. EPF coordinates. Strong impetus from key academicpartners and research organisations Industry expertise in medicines R&D,IT, capacity building Advisory bodies & codes committed toensure independence and goodgovernance• EMA, Swissmedic, MHRA, BfArM• Bioethics, genetics, HTA, economics, evidencebased med., patient advocacy• Ethics PanelWorking in partnershipwith strong governance
    • EUPATI – achievements by end of 2016Launched in 2012. First trainings in 2014. All languages in 2016.By 2017 we will have achieved: EUPATI platform fully loaded with training, education, informationmaterial in multiple languages EUPATI Patient Ambassador, Patient Journalist,Train-the-Trainer Programme in place Good practice guideline for patient involvement released Annual Conferences and Regional Workshops performed.Expert network established.
    • To address unmet needs and makeresearch patient-centric,more patient advocates needto be involved as partners in R&D.EUPATI will helpto make that happen.
    • Thank you!Web:www.patientsacademy.euTwitter: @eupatientsas well as: